Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC). Methods: We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with up-front chemotherapy. Associations between the use of RT and OS were evaluated. Results: We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65%) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P <.001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival. Conclusion: The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.

Original languageEnglish (US)
JournalHead and Neck
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Radiotherapy
Survival
Drug Therapy
Propensity Score
Proportional Hazards Models
Carcinoma, squamous cell of head and neck
Databases
Neoplasms

Keywords

  • metastatic head and neck squamous cell carcinoma
  • radiation therapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

@article{12bd176301384ddab7dc15484ac7d197,
title = "Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma",
abstract = "Background: To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC). Methods: We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with up-front chemotherapy. Associations between the use of RT and OS were evaluated. Results: We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65{\%}) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P <.001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival. Conclusion: The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.",
keywords = "metastatic head and neck squamous cell carcinoma, radiation therapy",
author = "Rafi Kabarriti and Sujith Baliga and Nitin Ohri and Chandan Guha and Shalom Kalnicki and Garg, {Madhur K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/hed.25476",
language = "English (US)",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma

AU - Kabarriti, Rafi

AU - Baliga, Sujith

AU - Ohri, Nitin

AU - Guha, Chandan

AU - Kalnicki, Shalom

AU - Garg, Madhur K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC). Methods: We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with up-front chemotherapy. Associations between the use of RT and OS were evaluated. Results: We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65%) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P <.001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival. Conclusion: The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.

AB - Background: To assess the association between radiation therapy (RT) use and overall survival (OS) for patients with metastatic head and neck squamous cell carcinomas (HNSCC). Methods: We analyzed the National Cancer Database to identify patients with newly diagnosed metastatic HNSCC from 2004 to 2013 who were treated with up-front chemotherapy. Associations between the use of RT and OS were evaluated. Results: We identified 3516 patients with metastatic HNSCC who were treated with chemotherapy; 2288 (65%) were also treated with RT. The addition of RT to chemotherapy was associated with prolonged survival (median: 13.6 vs 11.3 months, log-rank P <.001). After adjusting for other prognostic factors in a multivariable Cox model, propensity score matching and landmark analyses limited to patients who survived at least 3, 6, and 12 months after diagnosis, the use of RT remained associated with prolonged survival. Conclusion: The addition of RT to chemotherapy in the up-front management of metastatic HNSCC was associated with prolonged OS in this study.

KW - metastatic head and neck squamous cell carcinoma

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85058652752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058652752&partnerID=8YFLogxK

U2 - 10.1002/hed.25476

DO - 10.1002/hed.25476

M3 - Article

C2 - 30556318

AN - SCOPUS:85058652752

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -